IBDEI0A3 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10094,1,3,0)
 ;;=3^Type 2 DM w/ Prolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10094,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,10094,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,10095,0)
 ;;=E11.341^^51^588^72
 ;;^UTILITY(U,$J,358.3,10095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10095,1,3,0)
 ;;=3^Type 2 DM w/ Severe Nonprolif DM Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,10095,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,10095,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,10096,0)
 ;;=E11.349^^51^588^73
 ;;^UTILITY(U,$J,358.3,10096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10096,1,3,0)
 ;;=3^Type 2 DM w/ Severe Nonprolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,10096,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,10096,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,10097,0)
 ;;=E11.9^^51^588^74
 ;;^UTILITY(U,$J,358.3,10097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10097,1,3,0)
 ;;=3^Type 2 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,10097,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,10097,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,10098,0)
 ;;=H35.363^^51^588^18
 ;;^UTILITY(U,$J,358.3,10098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10098,1,3,0)
 ;;=3^Drusen of Macular,Bilateral
 ;;^UTILITY(U,$J,358.3,10098,1,4,0)
 ;;=4^H35.363
 ;;^UTILITY(U,$J,358.3,10098,2)
 ;;=^5005660
 ;;^UTILITY(U,$J,358.3,10099,0)
 ;;=H35.362^^51^588^19
 ;;^UTILITY(U,$J,358.3,10099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10099,1,3,0)
 ;;=3^Drusen of Macular,Left Eye
 ;;^UTILITY(U,$J,358.3,10099,1,4,0)
 ;;=4^H35.362
 ;;^UTILITY(U,$J,358.3,10099,2)
 ;;=^5005659
 ;;^UTILITY(U,$J,358.3,10100,0)
 ;;=H35.361^^51^588^20
 ;;^UTILITY(U,$J,358.3,10100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10100,1,3,0)
 ;;=3^Drusen of Macular,Right Eye
 ;;^UTILITY(U,$J,358.3,10100,1,4,0)
 ;;=4^H35.361
 ;;^UTILITY(U,$J,358.3,10100,2)
 ;;=^5005658
 ;;^UTILITY(U,$J,358.3,10101,0)
 ;;=H04.123^^51^588^21
 ;;^UTILITY(U,$J,358.3,10101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10101,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,10101,1,4,0)
 ;;=4^H04.123
 ;;^UTILITY(U,$J,358.3,10101,2)
 ;;=^5004465
 ;;^UTILITY(U,$J,358.3,10102,0)
 ;;=H35.32^^51^588^28
 ;;^UTILITY(U,$J,358.3,10102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10102,1,3,0)
 ;;=3^Exudative Age-Related Macular Degeneration
 ;;^UTILITY(U,$J,358.3,10102,1,4,0)
 ;;=4^H35.32
 ;;^UTILITY(U,$J,358.3,10102,2)
 ;;=^5005648
 ;;^UTILITY(U,$J,358.3,10103,0)
 ;;=H35.023^^51^588^29
 ;;^UTILITY(U,$J,358.3,10103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10103,1,3,0)
 ;;=3^Exudative Retinopathy,Bilateral
 ;;^UTILITY(U,$J,358.3,10103,1,4,0)
 ;;=4^H35.023
 ;;^UTILITY(U,$J,358.3,10103,2)
 ;;=^5005588
 ;;^UTILITY(U,$J,358.3,10104,0)
 ;;=H35.022^^51^588^30
 ;;^UTILITY(U,$J,358.3,10104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10104,1,3,0)
 ;;=3^Exudative Retinopathy,Left Eye
 ;;^UTILITY(U,$J,358.3,10104,1,4,0)
 ;;=4^H35.022
 ;;^UTILITY(U,$J,358.3,10104,2)
 ;;=^5005587
 ;;^UTILITY(U,$J,358.3,10105,0)
 ;;=H35.021^^51^588^31
 ;;^UTILITY(U,$J,358.3,10105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10105,1,3,0)
 ;;=3^Exudative Retinopathy,Right Eye
 ;;^UTILITY(U,$J,358.3,10105,1,4,0)
 ;;=4^H35.021
 ;;^UTILITY(U,$J,358.3,10105,2)
 ;;=^5005586
 ;;^UTILITY(U,$J,358.3,10106,0)
 ;;=H40.013^^51^588^32
 ;;^UTILITY(U,$J,358.3,10106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10106,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,10106,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,10106,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,10107,0)
 ;;=H40.012^^51^588^33
 ;;^UTILITY(U,$J,358.3,10107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10107,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,10107,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,10107,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,10108,0)
 ;;=H40.011^^51^588^34
 ;;^UTILITY(U,$J,358.3,10108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10108,1,3,0)
 ;;=3^Glaucoma Suspect,Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,10108,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,10108,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,10109,0)
 ;;=H52.03^^51^588^41
 ;;^UTILITY(U,$J,358.3,10109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10109,1,3,0)
 ;;=3^Hypermetropia,Bilateral
 ;;^UTILITY(U,$J,358.3,10109,1,4,0)
 ;;=4^H52.03
 ;;^UTILITY(U,$J,358.3,10109,2)
 ;;=^5006262
 ;;^UTILITY(U,$J,358.3,10110,0)
 ;;=H52.02^^51^588^42
 ;;^UTILITY(U,$J,358.3,10110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10110,1,3,0)
 ;;=3^Hypermetropia,Left Eye
 ;;^UTILITY(U,$J,358.3,10110,1,4,0)
 ;;=4^H52.02
 ;;^UTILITY(U,$J,358.3,10110,2)
 ;;=^5006261
 ;;^UTILITY(U,$J,358.3,10111,0)
 ;;=H52.01^^51^588^43
 ;;^UTILITY(U,$J,358.3,10111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10111,1,3,0)
 ;;=3^Hypermetropia,Right Eye
 ;;^UTILITY(U,$J,358.3,10111,1,4,0)
 ;;=4^H52.01
 ;;^UTILITY(U,$J,358.3,10111,2)
 ;;=^5006260
 ;;^UTILITY(U,$J,358.3,10112,0)
 ;;=H59.41^^51^588^44
 ;;^UTILITY(U,$J,358.3,10112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10112,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 1
 ;;^UTILITY(U,$J,358.3,10112,1,4,0)
 ;;=4^H59.41
 ;;^UTILITY(U,$J,358.3,10112,2)
 ;;=^5006426
 ;;^UTILITY(U,$J,358.3,10113,0)
 ;;=H59.42^^51^588^45
 ;;^UTILITY(U,$J,358.3,10113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10113,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 2
 ;;^UTILITY(U,$J,358.3,10113,1,4,0)
 ;;=4^H59.42
 ;;^UTILITY(U,$J,358.3,10113,2)
 ;;=^5006427
 ;;^UTILITY(U,$J,358.3,10114,0)
 ;;=H59.43^^51^588^46
 ;;^UTILITY(U,$J,358.3,10114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10114,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Stage 3
 ;;^UTILITY(U,$J,358.3,10114,1,4,0)
 ;;=4^H59.43
 ;;^UTILITY(U,$J,358.3,10114,2)
 ;;=^5006428
 ;;^UTILITY(U,$J,358.3,10115,0)
 ;;=H59.40^^51^588^47
 ;;^UTILITY(U,$J,358.3,10115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10115,1,3,0)
 ;;=3^Inflammation of Postprocedural Bleb,Unspec
 ;;^UTILITY(U,$J,358.3,10115,1,4,0)
 ;;=4^H59.40
 ;;^UTILITY(U,$J,358.3,10115,2)
 ;;=^5006425
 ;;^UTILITY(U,$J,358.3,10116,0)
 ;;=H54.8^^51^588^48
 ;;^UTILITY(U,$J,358.3,10116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10116,1,3,0)
 ;;=3^Legal Blindness,as Defined in USA
 ;;^UTILITY(U,$J,358.3,10116,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,10116,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,10117,0)
 ;;=H40.1231^^51^588^35
 ;;^UTILITY(U,$J,358.3,10117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10117,1,3,0)
 ;;=3^Glaucoma,Low-Tension,Mild Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,10117,1,4,0)
 ;;=4^H40.1231
 ;;^UTILITY(U,$J,358.3,10117,2)
 ;;=^5005768
 ;;^UTILITY(U,$J,358.3,10118,0)
 ;;=H40.1232^^51^588^36
 ;;^UTILITY(U,$J,358.3,10118,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10118,1,3,0)
 ;;=3^Glaucoma,Low-Tension,Moderate Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,10118,1,4,0)
 ;;=4^H40.1232
 ;;^UTILITY(U,$J,358.3,10118,2)
 ;;=^5005769
 ;;^UTILITY(U,$J,358.3,10119,0)
 ;;=H40.1233^^51^588^37
 ;;^UTILITY(U,$J,358.3,10119,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10119,1,3,0)
 ;;=3^Glaucoma,Low-Tension,Severe Stage,Bilateral
 ;;^UTILITY(U,$J,358.3,10119,1,4,0)
 ;;=4^H40.1233
 ;;^UTILITY(U,$J,358.3,10119,2)
 ;;=^5005770
 ;;^UTILITY(U,$J,358.3,10120,0)
 ;;=H52.13^^51^588^49
 ;;^UTILITY(U,$J,358.3,10120,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10120,1,3,0)
 ;;=3^Myopia,Bilateral
 ;;^UTILITY(U,$J,358.3,10120,1,4,0)
 ;;=4^H52.13
 ;;^UTILITY(U,$J,358.3,10120,2)
 ;;=^5006266
 ;;^UTILITY(U,$J,358.3,10121,0)
 ;;=H52.12^^51^588^50
 ;;^UTILITY(U,$J,358.3,10121,1,0)
 ;;=^358.31IA^4^2
